Predicting Human Bioavailability of Subcutaneously Administered Fusion Proteins and Monoclonal Antibodies Using Human Intravenous Clearance or Antibody Isoelectric Point
Author:
- 23 March 2023
- journal article
- research article
- Published by Springer Nature in The AAPS Journal
- Vol. 25 (3) , 1-11
Abstract
There has been an increasing trend towards subcutaneous (SC) delivery of fusion proteins and monoclonal antibodies (mAbs) in recent years versus intravenouKeywords
This publication has 26 references indexed in Scilit:
- Subcutaneous delivery of monoclonal antibodies: How do we get there?Journal of Controlled Release, 2018
- Hematopoietic cells as site of first-pass catabolism after subcutaneous dosing and contributors to systemic clearance of a monoclonal antibody in micemAbs, 2018
- In vitro model for predicting bioavailability of subcutaneously injected monoclonal antibodiesJournal of Controlled Release, 2018
- Quantitative prediction of therapeutic antibody pharmacokinetics after intravenous and subcutaneous injection in humanDrug Metabolism and Pharmacokinetics, 2017
- Biophysical properties of the clinical-stage antibody landscapeProceedings of the National Academy of Sciences, 2017
- Antibody Glycosylation and Its Impact on the Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies and Fc-Fusion ProteinsJournal of Pharmaceutical Sciences, 2015
- Mechanistic Determinants of Biotherapeutics Absorption Following SC AdministrationThe AAPS Journal, 2012
- Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administrationmAbs, 2012
- Which are the antibodies to watch in 2012?mAbs, 2012
- Antibodies to watch in 2010mAbs, 2010